November 15, 2016
ReveraGen Agrees to New In-License
Rockville’s own ReveraGen BioPharma, Inc., a Rockville Innovation Center tenant, granted an option to in-license vamorolone to Swiss company Actelion Ltd. This agreement marks the first tech transfer out of Children’s National Medical Center.
The impact of this agreement is big development in the treatment of Duchenne Muscular Dystrophy; vamorlone is essentially a steroid without the usual side effects. Should it be successful in Duchenne’s, it could be a blockbuster drug for the hundreds of auto-immune diseases that are often controlled with steroids.